A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.Nashat Gabrail, Ai‐Min Hui, Erika Hamilton et al.|Journal of Clinical Oncology|2021Cited by 25
A multicenter, open-label, phase I/II study of FN-1501 in patients with advanced solid tumors and acute myeloid leukemia.Raed Moh’d Taiseer Al-Rajabi, Ai‐Min Hui, Anis Hamid et al.|Journal of Clinical Oncology|2022Cited by 1